Verici Dx plc (LON:VRCI – Get Free Report)’s stock price traded down 16.9% during trading on Friday . The stock traded as low as GBX 5.20 ($0.07) and last traded at GBX 5.40 ($0.07). 236,310 shares traded hands during trading, a decline of 24% from the average session volume of 311,211 shares. The stock had previously closed at GBX 6.50 ($0.09).
Verici Dx Stock Performance
The stock’s 50 day moving average is GBX 6.80 and its two-hundred day moving average is GBX 7.25. The firm has a market capitalization of £13.95 million, a P/E ratio of -325.00 and a beta of 1.59. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.54 and a quick ratio of 8.49.
Verici Dx Company Profile
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
See Also
- Five stocks we like better than Verici Dx
- How to Buy Cheap Stocks Step by Step
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What is a Bond Market Holiday? How to Invest and Trade
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- How to Invest in the FAANG Stocks
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
